{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062888","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.895349+00:00","generated_at":"2026-06-08T05:14:09.841884+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Reneo Q3 net loss $19.2M; STRIDE topline results expected December 2023","bullets":["Net loss of $19.2M ($0.57/sh) vs $13.0M ($0.53/sh) in Q3 2022; R&D expense up to $13.6M.","Cash, cash equivalents, and short-term investments of $125.6M as of September 30, 2023.","Topline results from pivotal STRIDE study in adult PMM patients expected in December 2023.","Repurchased 576,443 shares for $4.4M from vTv Therapeutics in October 2023; shares retired.","Enrolled 88% of eligible STRIDE patients in open-label extension; 65 patients treated beyond 52 weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062888","json":"https://secwatch.observer/filing/0000950170-23-062888.json","markdown":"https://secwatch.observer/filing/0000950170-23-062888.md","text":"https://secwatch.observer/filing/0000950170-23-062888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023062888/0000950170-23-062888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023062888/rphm-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:14:09.841884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bab614322945b97b1097f19980370a6582e40444","claim":"OnKure Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $19.2 million, or $0.57 per share, EPS $0.57 per share.","evidence_excerpt":"Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023062888/0000950170-23-062888-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $19.2 million, or $0.57 per share"},{"label":"EPS","value":"$0.57 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}